SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Notification of transaction by Person Discharging Managerial Responsibilities ('PDMR')
Cambridge, UK, 23 November 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that Dr Stephen Parker, Non-Executive Chairman, purchased 277,777 ordinary shares of 0.025 pence each in the capital of the Company at a price of 3.6 pence per share on 23 November 2021.
The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further details.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Stephen Parker |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Non-Executive Chairman |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
Sareum Holdings plc |
|||
|
b) |
LEI |
213800PKERN2DY8FFM72 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc |
|||
|
|
|
||||
|
Identification code |
GB00B02RFS12 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Purchase of shares |
|||
|
c) |
Price(s) and volume(s) |
|
|||
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
3.6 pence |
277,777 |
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
277,777 ordinary shares |
||||
|
|
|
||||
|
- Price |
3.6 pence per share |
||||
|
|
|
||||
|
e) |
Date of the transaction |
23 November 2021 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (AIM) |
|||
For further information, please contact:
|
Sareum Holdings plc Tim Mitchell, CEO
|
01223 497 700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Peel Hunt LLP (Joint Corporate Broker) James Steel
|
020 7418 8900 |
|
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
|
MEDiSTRAVA Consulting (Financial PR) Mark Swallow / David Dible |
020 7638 9571 |
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
